Market research
0LW.F Neovacs S.A
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 59
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.25
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 59
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.25
About
About Neovacs S.A
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0LW.F discussion.
5 years, 5 months ago
Neovacs S.A is currently in a long term downtrend where the price is trading 69.8% below its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 37.0.
Based on the above factors, Neovacs S.A gets an overall score of 1/5.